The minimum projected sample size represents the number of primary practices required if: 1) the average number of children evaluated per year with asthma in a practice is the same; 2) the intercluster correlation coefficient is smaller than anticipated; 3) the baseline proportion of children treated with preventer medications is significantly worse than expected; and 4) we assume the minimum clinically important difference is bigger than 15%.
The maximum projected sample size represents the number of primary practices required if:
1) average number of children evaluated per year with asthma in a practice is the same; 2) intercluster correlation coefficient is larger than anticipated; 3) the baseline proportion of children treated with preventer is significantly better than expected; and 4) we assume the minimum clinically important difference is smaller than 15%. Sample size calculation: To calculate our sample size using our primary outcomeproportion of symptomatic asthmatic children in the baseline and follow-up periods that are appropriately treated with a preventer -we used data from all Alberta primary care practices that use Med Access as their EMR. The median number of children (< 18 yrs) with asthma evaluated each year in these practices is 70, the estimated proportion of 'success' is 30%, and the estimated intraclass correlation coefficient (ICC) is 0.025 (which is consistent with ICC values reported for primary care research) [1] . To estimate the minimal clinically significant change for this trial, we conducted a survey of practitioners which determined that a 15% absolute change in preventer treatment was clinically important. Using the above values (cluster size = 70, ICC = 0.025, proportion of 'success' in control arm = 30%, minimal clinically important improvement = + 15%, that is, proportion of success in intervention arm=45%) and the approach of Hayes and Bennett [2] , we determined 11 clusters per arm (or 22 practices ) would provide us with more than 90% power, setting an alpha of 0.05. This power suggests our sample size is robust.
Minimum
Design Justification: Based on recommendations by Donner, we will not use a matched pair design because of lack of baseline information on the primary outcome, rate of preventive therapy in practices [3] [4] . Although our project intervention has 2 components (pathway and CDM professional training), we have chosen not to use a factorial study design because these components will be highly interwoven, and, we anticipate, synergistic. A review of factorial studies highlights that if synergy between interventions occurs [5] , factorial design can result in inadequate power to detect differences between interventions.
